Avacta Group Company Description

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally.

Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities.

The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors.

The company was incorporated in 2003 and is headquartered in London, the United Kingdom.

Avacta Group Plc

Country	United Kingdom
Founded	2003
Industry	Biotechnology
Sector	Healthcare
Employees	151
CEO	Christina Coughlin

Contact Details

Address: Scale Space White City Imperial College Campus London, W12 7RZ United Kingdom
Phone	44 203 9110353
Website	avacta.com

Stock Details

Ticker Symbol	AVCT
Exchange	London Stock Exchange AIM
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00BYYW9G87
SIC Code	8731

Key Executives

Name	Position
Christina Coughlin	Chief Executive Officer
Brian Hahn	Chief Financial Officer
Karen Harrison	Chief Operating Officer